AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17134892
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg daily for 3 years
Trial: 17134892
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg daily for 3 years (in node-positive subgroup)
Trial: 17134892
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg daily for 3 years (in ER and PR positive subgroup)
Trial: 15915033
Drug: Postoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative epidural analgesia (4 days of continuous infusion of 4 ml/h bupivacaine, 0.125%, and 50 mug/ml morphine)
Trial: 12495789
Drug: Ketamine psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine psychotherapy (KPT) with a high dose of ketamine (2.0 mg/kg im)
Trial: 12495789
Drug: Ketamine psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine psychotherapy (KPT) with a low dose of ketamine (0.2 mg/kg im)
Trial: 7644901
Drug: Enriched commands
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched commands (e.g., 'wave your hands as a conductor')
Trial: 7644901
Drug: Basic commands
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic commands (e.g., 'wave your hands')
Trial: 2671059
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of brotizolam
Trial: 2671059
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of flurazepam
Trial: 30771737
Drug: Trimetazidine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (35 mg bid)
Trial: 28292385
Drug: Mitomycin-C injection
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C injection 1 month before surgery
Trial: 28292385
Drug: Mitomycin-C injection
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C injection 24 hours before surgery
Trial: 20704642
Drug: 1% hydroalcoholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hydroalcoholic testosterone gel (50 mg/5 g gel), increased to 10 mg if clinically unsatisfactory
Trial: 15490268
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg daily for 360 days
Trial: 11309547
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg once daily, 400 mg on day 1)
Trial: 11309547
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg once daily)
Trial: 9603272
Drug: Women's sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women's sensitive approach to drug-user treatment
Trial: 9603272
Drug: Treatment discharge
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment discharge status
Trial: 26515712
Drug: Engaged in
RxNorm normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engaged in therapy (attended ≥ 6 sessions)
Trial: 23053464
Drug: M4 (magnesium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M4 (magnesium, 4 g)
Trial: 9492915
Drug: Pyrantel pamoate
RxNorm normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel pamoate at a single dose rate of 10 mg/kg body weight
Trial: 10450449
Drug: Albendazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (single 400 mg dose)
Trial: 3555385
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate 25 mg every two weeks
Trial: 3555385
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate 5 mg every two weeks
Trial: 3555385
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate with dosage adjustment up to 10 mg
Trial: 3555385
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate 25 mg
Trial: 3555385
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate 5 mg
Trial: 28043438
Drug: Baroreflex Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex Activation Therapy (BAT) plus medical therapy
Trial: 25904747
Drug: Daily acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily acyclovir treatment
Trial: 23685637
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone (0.5 μg/kg/min)
Trial: 16314619
Drug: Efaproxiral at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efaproxiral at 75 or 100 mg/kg
Trial: 10984077
Drug: Insulin (Actrapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (Actrapid MC Novo, 0.1 IU/kg, i.v.)
Trial: 10984077
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (50 g and 100 g)
Trial: 9010703
Drug: Pranlukast (112.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (112.5 to 675 mg, oral, every 12 h)
Trial: 9010703
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of pranlukast
Trial: 9010703
Drug: Evening doses
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening doses of pranlukast
Trial: 1476921
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) administered in fasting conditions
Trial: 1476921
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) administered after food ingestion (low-fat or fat-rich breakfast)
Trial: 16174272
Drug: Listerine mouthwash
RxNorm normalized name: Listerine Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine mouthwash (10 ml, rinsed twice a day for 60 seconds)
Trial: 16174272
Drug: 0.1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% chlorhexidine (CHX) mouthwash (10 ml, rinsed twice a day for 60 seconds)
Trial: 16174272
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (10 ml, rinsed twice a day for 60 seconds)
Trial: 8667921
Drug: Longer maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer maintenance chemotherapy (2 years)
Trial: 8667921
Drug: Intensive reinduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive reinduction chemotherapy during maintenance
Trial: 29265496
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication + proton pump inhibitor for 7 weeks
Trial: 29265496
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor for 8 weeks (non-eradication group)
Trial: 24337358
Drug: Biological condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological condition (N=176)
Trial: 22596166
Drug: Study therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study therapy (intensive or conventional methotrexate-based treatment)
Trial: 20634720
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg moxonidine (MOX) daily
Trial: 15897698
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 10 days
Trial: 11916760
Drug: CSII plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII plus 200 mg alpha-tocopherol/d
Trial: 9840721
Drug: Etoposide (100mg/m2/1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (100mg/m2/1 h) administered immediately before and at the end (24 h) of MTX treatment
Trial: 9840721
Drug: Etoposide (100mg/m2/1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (100mg/m2/1 h) administered at 24 and 48 h after starting MTX infusion
Trial: 9840721
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (5g/m2/24 h)
Trial: 7500751
Drug: Desogestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing oral contraceptive (30 micrograms ethinyloestradiol)
Trial: 7500751
Drug: Low-dose OCs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OCs with a third-generation progestagen
Trial: 2225484
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg p.o. at -60 min)
Trial: 495512
Drug: Single 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mg oral dose of prazosin (Group A, no. = 7)
Trial: 495512
Drug: Oral prazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prazosin, 2 mg every 8 hours for 24 hours (Group B, no. = 7)
Trial: 28340281
Drug: FND with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FND with concurrent rituximab
Trial: 22029223
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of quetiapine fumarate 25 mg film-coated tablet
Trial: 22029223
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of quetiapine fumarate 25 mg film-coated tablet
Trial: 17917907
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily activities (Control)
Trial: 1149490
Drug: co-trimoxazole (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-trimoxazole (480 mg trimethoprim and 2,400 mg sulphamethoxazole daily)
Trial: 1149490
Drug: tetracycline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetracycline (2 g daily)
Trial: 28177187
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg (T+C)
Trial: 26298786
Drug: JZP-110 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4)
Trial: 20508536
Drug: High-protein recovery
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein recovery diet (1.4/0.7/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Trial: 20508536
Drug: Isocaloric control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric control condition (2.1/0.1/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Trial: 18444947
Drug: Heparin-coated autotransfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated autotransfusion system
Trial: 18444947
Drug: Non-heparin-coated autotransfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-coated autotransfusion system
Trial: 12906366
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg capsule in the evening)
Trial: 10784307
Drug: PGI2 5
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 5 microg x ml(‐1)
Trial: 10784307
Drug: PGI2 10
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 10 microg x ml(‐1)
Trial: 9038439
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine (single dose 2 h before surgery)
Trial: 9038439
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine (every 12 h for 2 days before surgery)
Trial: 1889841
Drug: Renin inhibitor
RxNorm normalized name: Renin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin inhibitor Ro 42-5892 (0.3 mg/kg injected at 30 minutes, followed by infusion at 0.1 mg/kg/hr from 30 to 240 minutes)
Trial: 1889841
Drug: Ang II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ang II infusion (2 ng/kg/min from 0 to 60 minutes and 4 ng/kg/min from 60 to 120 minutes)
Trial: 1889841
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of Ang II and Ro 42-5892 (same doses as above)
Trial: 6133645
Drug: Beta-blocking drugs
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocking drugs (specific drugs not mentioned)
Trial: 20558918
Drug: Intravenous cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cephazolin (CEZ) at 2 g/day for 5 days
Trial: 20558918
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin (LVFX) at 300 mg/day for 5 days
Trial: 7561823
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (anticholinergic agents)
Trial: 1973718
Drug: Ceftriaxone 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 4 g every 24 hours for 5 to 7 days
Trial: 1973718
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g every 12 hours for 5 to 7 days
Trial: 1973718
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g every 24 hours for 5 to 7 days
Trial: 1973718
Drug: Short-course treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course treatment regimens (any of the above)
Trial: 17356507
Drug: mepivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine + ropivacaine 40 mg
Trial: 17356507
Drug: mepivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine + ropivacaine 25 mg
Trial: 17356507
Drug: mepivacaine 1.5%
RxNorm normalized name: mepivacaine 1.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine 1.5% (300 mg)
Trial: 16356430
Drug: Initial L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial L-thyroxine dose of 50 mug
Trial: 16356430
Drug: Initial L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial L-thyroxine doses (50 mug, 37.5 mug)
Trial: 7648821
Drug: Urinary albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary albumin excretion rate (UAE)
Trial: 328880
Drug: Ketoprofen (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (150-300 mg daily)
Trial: 328880
Drug: Ibuprofen (1200-2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200-2400 mg daily)
Trial: 31712348
Drug: Intensive skin
RxNorm normalized name: Remedy Intensive Skin Therapy Hydraguard D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive skin surveillance programme consisting of 3D total-body photography, sequential digital dermoscopy, and melanoma-risk stratification.
Trial: 28206732
Drug: MPFF 1000-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 1000-mg oral suspension once daily
Trial: 28206732
Drug: MPFF 500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 500-mg tablets twice daily
Trial: 19336514
Drug: Inhaled GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled GH
Trial: 19336514
Drug: Subcutaneous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GH (sc GH)
Trial: 19336514
Drug: Inhaled GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled GH and sc GH
Trial: 16672024
Drug: Resorbable screws
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resorbable screws made of poly (D.L‐lactide) acid (PDLLA)
Trial: 15475033
Drug: Aged Garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged Garlic Extract (AGE) 4 ml
Trial: 1839436
Drug: Amlodipine (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (once daily)
Trial: 1839436
Drug: Captopril (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (twice daily)
Trial: 6223583
Drug: SPG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPG (20 mg twice a week or 40 mg once a week) in combination with tegafur
Trial: 6223583
Drug: SPG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPG (20 mg twice a week or 40 mg once a week)
Trial: 27918841
Drug: summerMAX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: summerMAX treatment (5-week program targeting social skills, nonliteral language skills, face-emotion recognition, interest expansion)
Trial: 27918841
Drug: summerMAX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: summerMAX treatment
Trial: 17444308
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus 0.25 mg/kg ketamine
Trial: 9696475
Drug: Capsaicin treatment
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin treatment
Trial: 2782361
Drug: Hydration (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration (5% dextrose in lactated Ringer's solution, intravenous bolus and continuous infusion)
Trial: 31173127
Drug: High NUF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NUF rate (>1.75 mL/kg/h)
Trial: 31173127
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in NUF rate (every 0.5 mL/kg/h)
Trial: 28651403
Drug: Daily group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily group
Trial: 28651403
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between daily and intermittent groups
Trial: 15317700
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (15 mg/kg) half an hour before surgery
Trial: 15317700
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (0.5 mg/kg) for 2 weeks, tapered postoperatively
Trial: 15317700
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Intravenous methylprednisolone and Oral prednisolone)
Trial: 9071936
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g coarse bran
Trial: 9071936
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g inert plastic particles
Trial: 9071936
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g ispaghula
Trial: 2881183
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Beta-blockade + Nifedipine)
Trial: 30958141
Drug: Stress reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress reduction intervention (5-weekly sessions)
Trial: 27181070
Drug: biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: biphasic insulin aspart 30
Trial: 23848405
Drug: 1 μg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg.kg(‐1) intranasal dexmedetomidine with 3 mg.kg(‐1) oral ketamine (Group 1)
Trial: 23848405
Drug: 1 μg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 2)